FindTrial
Sign In

Post Marketing Clinical Study of Aripiprazole in Patients with Schizophrenia - Effects on Glucose Metabolism-

Post Marketing Clinical Study of Aripiprazole in Patients with Schizophrenia - Effects on Glucose Metabolism-

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1080220320
Enrollment
Unknown
Registered
2006-11-09
Start date
2006-11-09
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

investigational material(s) Generic name etc : Aripiprazole INN of investigational material : Therapeutic category code : 117 Psychotropic agents Dosage and Administration for Investigational materia

Sponsors

Otsuka Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Schizophrenic patients, who meet the F20 criteria of ICD-10, without hyperglycemia and diabetes mellitus or any history thereof

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Effects on variables relating to glucose metabolism, efficacy (PANSS and CGI-I), and safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026